Radioligand therapy (RLT), targeting the PSMA, showed desired antitumor effects by combining the therapeutic radionuclides with the PSMA ligands and delivering a high-radiation dose to the targeted tumor cells (Sgouros et al., 2020). The gene discussed is FOLH1; the disease is neoplasm.